Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

BMC Gastroenterology

Volumn 6, Issue , 2006, Pages

  Ratziu, Vlad ^a   Massard, Julien ^a   Charlotte, Frederic ^a   Messous, Djamila ^a   Imbert Bismut, Françoise ^a   Bonyhay, Luninita ^a   Tahiri, Mohamed ^a   Munteanu, Mona ^b   Thabut, Dominique ^a   Cadranel, Jean François ^c   Le Bail, Brigitte ^d   de Ledinghen, Victor ^d   Poynard, Thierry ^a   Grimaldi, André ^a,d   Giral, Philippe ^a,d   Bruckert, Eric ^a,d   Turpin, Gérard ^a,d   Heurtier, Agnès ^a,d   Gombert, Sophie ^a,d   Lamaison, Francine ^a,d   Moussalli, Joseph ^a,d   Le Galvez, Sophie ^a,d   Benhamou, Yves ^a,d   D'Arrondel, Cecilia ^a,d   Cocaul, Arnaud ^a,d   Ravalet, Isabelle ^a,d   Combet, Stépahnie ^a,d   Podevin, Philippe ^d,e   Basdevant, Arnaud ^d,f   Slama, Gérard ^d,f   Clement, Karine ^d,f   Serfaty, Lawrence ^d,g   Housset, Chantal ^d,g   Capeau, Jacqueline ^d,g   Blanchi, Alain ^d,h   Pilette, Christophe ^d,h   Bourlière, Marc ^d,i   Oulès, Valérie ^d,i   Renou, Christophe ^d,j   Capron, Dominique ^d,k   Oberti, Frédéric ^d,l   Calès, Paul ^d,l   Tran, Albert ^d,m   Gelsi, Eve ^d,m   Gournay, Jèrôme ^d,n   Vallet Pichard, Anais ^d,o   Pol, Stanislaw ^d,o   Causse, Xavier ^d,p   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b AP HP Groupe Hospitalier Pitié Salpêtrière ^*  (France)

^c Centre Hospitalier de Creil   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e Hôpital Haut Lévèque ^*  (France)

^f HÔTEL DIEU   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h CENTRE HOSPITALIER DU MANS   (France)

ⁱ HÔPITAL SAINT JOSEPH   (France)

^j Hôpital d'Hyères   (France)

^k Hôpital d'Amiens   (France)

^l Hopital d'Angers   (France)

^m Hôpital de Nice   (France)

ⁿ Centre de Nantes   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p Hôpital d'Orleans   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BLOOD DONOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER SINUSOID; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PREDICTION; PREDICTIVE VALIDITY; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SENSITIVITY AND SPECIFICITY; AGE; ALGORITHM; AUTOANALYSIS; BIOPSY; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EVALUATION; FATTY LIVER; LIVER; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MIDDLE AGED; PATHOLOGY; PHOTOMETRY; PREDICTIVE VALUE; RISK FACTOR; SEX DIFFERENCE; STATISTICAL ANALYSIS;

AGE FACTORS; ALANINE TRANSAMINASE; ALGORITHMS; ALPHA-MACROGLOBULINS; APOLIPOPROTEIN A-I; AUTOANALYSIS; BILIRUBIN; BIOLOGICAL MARKERS; BIOPSY; DATA INTERPRETATION, STATISTICAL; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HAPTOGLOBINS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 33644607568     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-6-6     Document Type: Article

References (51)

1. Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-25.
2. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-31.
3. Charlton M: Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenteral Hepatol 2004, 2:1048-58.
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M: Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenteralogy 2002, 123:134-140.
5. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002, 35:1485-93.
6. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T: Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123.
7. VanNess MM, Diehl AM: Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989, 111:473-478.
8. Sorbi D, Boynton J, Lindor KD: The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999, 94:1018-1022.
9. McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990, 99:1396-400.
10. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver(AFEF). Hepottology 2000, 32:477-81.
11. Poynard T, Ratziu V, Bedossa P: Appropriateness of liver biopsy. Can J Gastroenterol 2000, 14:543-8.
12. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, for the LIDO Study Group: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
13. Younossi ZM, Gramlich T, Liu YC, Matteoni C. Petrelli M, Goldblum J, Rybicki L, McCullough AJ: Non-alcoholic fatty liver disease: asessment of variability in pathologic interpretations. Mod Pathol 1998, 11:560-565.
14. Bellentani S, Bedogni G, Miglioli L, Tiribelli C: The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004, 16:1087-93.
15. Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
16. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
17. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD: Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991, 43:26-31.
18. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-50.
19. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-75.
20. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002, 9:128-33.
21. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T: Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002, 97:2419-25.
22. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E. Thabut D, Myers RP, Poynard T: A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (Fibro Test) and activity (Acti Test) in patients with chronic liver disease. Comp Hepatol 2002, 1:3.
23. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T: Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004, 42:323-33.
24. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T: Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. Aids 2003, 17:721-5.
25. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T: Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-30.
26. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J: Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003, 38:481-92.
27. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V: Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. Clin Chem 2004, 50:1344-55.
28. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8.
29. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaoui A, Slama A, Blin P, Thibault V, Parvaz P, Munteanu M, Trepo C: Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gast 2005, 100:1970-80.
30. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T: Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005, 3:167-74.
31. Callewaert N, Van Vlierberghe H, Van Herke A, Laroy W, Delanghe J, Contreras R: Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004, 10:429-34.
32. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-50.
33. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V: Fibro Test-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005, 5:15-21.
34. Halfon P, Bourliere M, Deydier R, Portal I, Renou R, Bertrand J, Trana A, Rosenthal A, Rotily M, Sattonet A, D O: Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C. Am J Gastro 2006 in press.
35. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-21.
36. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-45.
37. Zhou X, Obuchowski N, McClish D: Statistical Methods in Diagnostic Medicine Edited by: John Wiley & Sons I. New York New York, 2002.
38. Laine F, Bendavid C, Moirand R, Tessier S, Perrin M, Guillygomarc'h A, Guyader D, Calon E, Renault A, Brissot P, Turlin B, Deugnier Y: Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology 2004, 39:1639-46.
39. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
40. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-92.
41. Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, Gargiulo G, Gennarelli N, Lobello R: Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 2004, 41:751-7.
42. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Kinjo F, Saito A: Clinical usefulness of biochemical markers of liver fibrosis in patients with non-alcoholic fatty liver disease. World J Gostroenterol 2005, 11:255-9.
43. Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJP, on behalf of the European Liver Fibrosis Group: Serum Markers Detect the Presence of Liver Fibrosis: A Cohort Study. Gastroenterology 2004, 127:1704-1713.
44. Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J: Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 2005, 128:1146-8. author reply 1148.
45. Munteanu M, Messous D, Thabut D, Imbert-Bismut F. Jouys M, Massard J, Piton A, Bonyhay L. Ratziu V, Hainque B, Poynard T: Intraindividual fasting versus postprandial variation of biochemical markers of liver fibrosis (Fibro Test) and activity (ActiTest). Comp Hepatol 2004, 3:3.
46. Barrett AJ, Starkey PM: The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973, 133:709-24.
47. Zahnd GR, Scheidegger JJ: Role of alpha-2-macroglobulin of human serum in the fixation in vitro of iodine-131 labeled bovine insulin. Helv Med Acta 1963, 30:506-11.
48. Gray RS, James K, Merriman J, Starkey IR, Elton RA, Clarke BF, Duncan LJ: Alpha 2-macroglobulin and proliferative retinopathy in type 1 diabetes. Horm Metab Res 1982, 14:389-92.
49. Chu CT, Rubenstein DS, Enghild JJ, Pizzo SV: Mechanism of insulin incorporation into alpha 2-macroglobulin: implications for the study of peptide and growth factor binding. Biochemistry 1991, 30:1551-60.
50. Westwood M, Aplin JD, Collinge IA, Gill A, White A, Gibson JM: alpha 2-Macroglobulin: a new component in the insulin-like growth factor/ insulin-like growth factor binding protein-1 axis. J Biol Chem 2001, 276:41668-74.
51. Sakai K, Lowman HB, Clemmons DR: Increases in free, unbound insulin-like growth factor 1 enhance insulin responsiveness in human hepatoma G2 cells in culture. J Biol Chem 2002, 277:13620-7.